Gilead and Kite Present Innovative Blood Cancer Therapies at ASH 2025
Gilead and Kite Unveil Advances in Blood Cancer Treatment at ASH 2025
Gilead Sciences, headquartered in Foster City, California, and its subsidiary Kite, based in Santa Monica, California, are making headlines at the 67th Annual Meeting of the American Society of Hematology (ASH) 2025. Scheduled from December 6 to 9, the event will see them present a total of 21 abstracts, including five oral presentations. The data being shared reflect significant advancements in the delivery of innovative cell therapies aimed at treating blood cancers, marking an important moment for the field of hematology.
Cindy Perettie, Executive Vice President at Kite, commented on the importance of the findings, stating, "Kite is dedicated to moving forward with cell therapies as potential pathways to cures. The data being presented at ASH underscores meaningful progress toward that goal. This time, we will share the latest results from the pivotal Phase II iMMagine-1 study of anitocabtagene autoleucel (anito-cel) in patients with recurrent/refractory multiple myeloma. These insights hold promise for improving access to cancer care in our communities and could ease the burden for patients and their caregivers."
Latest Data on Anitocabtagene Autoleucel (anito-cel)
The presentation of key data regarding anito-cel includes updates on the ongoing Phase II iMMagine-1 pivotal trial, confirming that there have been no reported instances of late-onset neurological toxicities such as Parkinsonism, neurological paralysis, Guillain-Barré syndrome, or immune-related enteropathy thus far. This milestone marks a crucial aspect of ensuring patient safety and enhancing treatment options.
Next-Generation CAR T-cell Therapy Developments
In addition to presenting outcomes from the iMMagine-1 study, Kite will offer new insights from the KITE-363 and KITE-753 trials, both of which focus on next-generation bispecific CAR T-cell therapies. These innovative treatments target two antigens (CD19 and CD20) present on cancer cells, deploying two co-stimulatory domains (CD28 and 4-1BB). This dual-targeting approach not only narrows the potential for cancer to evade treatment but also enhances safety, allowing for treatments to be administered in outpatient settings.
Efficacy of Yescarta® in Patients
Major findings will also focus on Yescarta® (axicabtagene ciloleucel), specifically regarding its survival outcomes in patients with recurrent/refractory large B-cell lymphoma (LBCL) who are eligible for autologous stem cell transplant (ASCT). Results from the four-year follow-up of the ZUMA-7 trial will be presented alongside data from the ALYCANTE study, which assessed non-eligible patients for ASCT. The consistent patterns of efficacy, safety, and quality of life improvements seen in both cohorts support the expanded use of Yescarta, signaling enhanced potential for this one-time treatment approach.
Summary of Abstracts and Presentation Times (Eastern Standard Time)
- - Presentation Title: Clinical Data on Axicabtagene Ciloleucel
- Venue: OCCC - Tangerine Ballroom F3-4
- - Brexucabtagene Autoleucel Clinical Data
- Venue: OCCC - Tangerine Ballroom F3-4
- - Anitocabtagene Autoleucel Clinical Data
- Venue: OCCC - West Halls D1
- - Translational Medicine Research
- Venue: OCCC - W331
- - Real-World Evidence and Quality of Life Improvement
- Venue: OCCC - West Halls B3-B4
For full details of the abstracts, please visit ASH Conference Program.
In summary, Gilead and Kite's presentations at ASH 2025 represent a significant leap forward in the treatment of blood cancers, with new data that promises to enhance patient care and outcomes. Their commitment to innovation continues to pave the way for breakthroughs in cancer therapies.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.